Novozymes A/S - NVZMY Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NVZMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View NVZMY analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 12-month price objectives for Novozymes A/S's stock. Their NVZMY share price forecasts range from $370.00 to $370.00. On average, they expect the company's stock price to reach $370.00 in the next twelve months. This suggests a possible upside of 663.5% from the stock's current price.
View analysts price targets for NVZMY or view top-rated stocks among Wall Street analysts.

Novozymes A/S's stock was trading at $50.46 at the beginning of 2023. Since then, NVZMY shares have decreased by 4.0% and is now trading at $48.46.
View the best growth stocks for 2023 here.

Novozymes A/S saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 400 shares, a decline of 42.9% from the February 13th total of 700 shares. Based on an average daily trading volume, of 30,000 shares, the short-interest ratio is currently 0.0 days.
View Novozymes A/S's Short Interest.

Novozymes A/S (OTCMKTS:NVZMY) announced its quarterly earnings data on Wednesday, April, 29th. The biotechnology company reported $0.42 earnings per share for the quarter, meeting the consensus estimate of $0.42. The biotechnology company had revenue of $558.75 million for the quarter. Novozymes A/S had a net margin of 20.08% and a trailing twelve-month return on equity of 26.96%.

Novozymes A/S announced a dividend on Thursday, March 2nd. Stockholders of record on Monday, March 6th will be paid a dividend of $0.5898 per share on Wednesday, March 22nd. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Friday, March 3rd.
Read our dividend analysis for NVZMY.

Putnam BioRevolution ETF holds 3,439 shares of NVZMY stock, representing 3.58% of its portfolio.

Novozymes A/S (OTCMKTS:NVZMY) pays an annual dividend of $0.57 per share and currently has a dividend yield of 1.17%.
Read our dividend analysis for NVZMY.

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVZMY stock can currently be purchased for approximately $48.46.

Novozymes A/S (OTCMKTS:NVZMY) has a market capitalization of $11.01 billion and generates $2.38 billion in revenue each year.

The company employs 6,527 workers across the globe.

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The official website for the company is www.novozymes.com. The biotechnology company can be reached via phone at (454) 446-0000, via email at novozymesir@novozymes.com, or via fax at 45-4446-9999.